{
  "meta": {
    "data_length": 2,
    "message": "Statements retrieved successfully",
    "request_url": "http://api.moalmanac.org/statements?agent_id=fda&proposition_id=106",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.04172,
    "timestamp_received": "2026-05-15T13:17:30.782643+00:00Z",
    "timestamp_returned": "2026-05-15T13:17:30.824363+00:00Z",
    "trace_id": "56863e91-60fe-4aa6-8671-9d287380dedd"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-05-07"
  },
  "data": [
    {
      "id": 610,
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
      "contributions": [
        {
          "id": 1,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Additional FDA approvals for initial version",
          "date": "2025-01-10"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda.imjudo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Imjudo (tremelimumab-actl) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "AstraZeneca AB.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Imjudo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "tremelimumab-actl",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 761270,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2022-11-10",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:fda.imjudo:0",
        "indication": "IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.",
        "initial_approval_date": "2022-11-10",
        "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf",
        "description": "The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
        "raw_biomarkers": "no sensitizing EGFR mutation or ALK genomic tumor aberrations",
        "raw_cancer_type": "metastatic non-small cell lung cancer",
        "raw_therapeutics": "Imjudo (tremelimumab-actl) in combination with durvalumab and platinum-based chemotherapy",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:fda.imjudo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Imjudo (tremelimumab-actl) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "AstraZeneca AB.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Imjudo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "tremelimumab-actl",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 761270,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2022-11-10",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 106,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 34,
            "name": "Wild type ALK",
            "genes": [
              {
                "id": 2,
                "name": "ALK",
                "primaryCoding": {
                  "id": "hgnc:427",
                  "code": "HGNC:427",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"
                  ]
                },
                "mappings": [
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000171094",
                      "code": "ENSG00000171094",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000171094"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:238",
                      "code": "238",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/238"
                      ]
                    }
                  },
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_004304.5",
                      "code": "NM_004304.5",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "2p23.2-p23.1"
                  },
                  {
                    "name": "location_sortable",
                    "value": "02p23.2-p23.1"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Wild type"
              },
              {
                "name": "present",
                "value": true
              }
            ]
          },
          {
            "id": 35,
            "name": "Wild type EGFR",
            "genes": [
              {
                "id": 17,
                "name": "EGFR",
                "primaryCoding": {
                  "id": "hgnc:3236",
                  "code": "HGNC:3236",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"
                  ]
                },
                "mappings": [
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_005228.5",
                      "code": "NM_005228.5",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000146648",
                      "code": "ENSG00000146648",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000146648"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:1956",
                      "code": "1956",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/1956"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "7p11.2"
                  },
                  {
                    "name": "location_sortable",
                    "value": "07p11.2"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Wild type"
              },
              {
                "name": "present",
                "value": true
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 47,
          "conceptType": "Disease",
          "name": "Non-Small Cell Lung Cancer",
          "primaryCoding": {
            "id": "oncotree:NSCLC",
            "code": "NSCLC",
            "name": "Non-Small Cell Lung Cancer",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 22,
          "membership_operator": "AND",
          "therapies": [
            {
              "id": 45,
              "conceptType": "Drug",
              "name": "Tremelimumab",
              "primaryCoding": {
                "id": "ncit:C49085",
                "code": "C49085",
                "name": "Tremelimumab",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:2619313",
                    "code": "2619313",
                    "name": "tremelimumab",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2619313"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:741851",
                    "code": "741851",
                    "name": "tremelimumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/741851"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:2054101000122107",
                    "code": "2054101000122107",
                    "name": "Tremelimumab",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=2054101000122107&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1450218",
                    "code": "1450218",
                    "name": "Tremelimumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1450218"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "CTLA-4 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Immunotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 50,
              "conceptType": "Drug",
              "name": "Gemcitabine",
              "primaryCoding": {
                "id": "ncit:C66876",
                "code": "C66876",
                "name": "Gemcitabine",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:12574",
                    "code": "12574",
                    "name": "gemcitabine",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=12574"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1314924",
                    "code": "1314924",
                    "name": "gemcitabine",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1314924"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:386920008",
                    "code": "386920008",
                    "name": "Gemcitabine",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=386920008&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4305105",
                    "code": "4305105",
                    "name": "Gemcitabine",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4305105"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Antimetabolite"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 37,
              "conceptType": "Drug",
              "name": "Carboplatin",
              "primaryCoding": {
                "id": "ncit:C1282",
                "code": "C1282",
                "name": "Carboplatin",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:40048",
                    "code": "40048",
                    "name": "carboplatin",
                    "system": "RxNorm",
                    "systemVersion": "20250602",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=40048"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4299846",
                    "code": "4299846",
                    "name": "Carboplatin",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4299846"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:386905002",
                    "code": "386905002",
                    "name": "Carboplatin",
                    "system": "SNOMED",
                    "systemVersion": "2026-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=386905002&edition=MAIN/2026-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1344905",
                    "code": "1344905",
                    "name": "carboplatin",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1344905"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Platinum-based chemotherapy"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 44,
              "conceptType": "Drug",
              "name": "Durvalumab",
              "primaryCoding": {
                "id": "ncit:C103194",
                "code": "C103194",
                "name": "Durvalumab",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:1919503",
                    "code": "1919503",
                    "name": "durvalumab",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1919503"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1594034",
                    "code": "1594034",
                    "name": "durvalumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1594034"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:735230005",
                    "code": "735230005",
                    "name": "Durvalumab",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=735230005&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:42536415",
                    "code": "42536415",
                    "name": "Durvalumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/42536415"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "PD-1/PD-L1 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Immunotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            }
          ]
        }
      }
    },
    {
      "id": 120,
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
      "contributions": [
        {
          "id": 1,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Additional FDA approvals for initial version",
          "date": "2025-01-10"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda.imfinzi",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Imfinzi (durvalumab) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "AstraZeneca UK Limited.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Imfinzi",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "durvalumab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2017-05-01",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 761069,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-08-15",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:fda.imfinzi:0",
        "indication": "IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations.",
        "initial_approval_date": "2022-11-10",
        "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf",
        "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
        "raw_biomarkers": "no sensitizing EGFR mutations or ALK genomic aberrations",
        "raw_cancer_type": "metastatic non-small cell lung cancer",
        "raw_therapeutics": "Imfinzi (durvalumab) in combination with tremelimumab-actl and platinum-based chemotherapy",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:fda.imfinzi",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Imfinzi (durvalumab) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "AstraZeneca UK Limited.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Imfinzi",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "durvalumab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2017-05-01",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 761069,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-08-15",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 106,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 34,
            "name": "Wild type ALK",
            "genes": [
              {
                "id": 2,
                "name": "ALK",
                "primaryCoding": {
                  "id": "hgnc:427",
                  "code": "HGNC:427",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"
                  ]
                },
                "mappings": [
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000171094",
                      "code": "ENSG00000171094",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000171094"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:238",
                      "code": "238",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/238"
                      ]
                    }
                  },
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_004304.5",
                      "code": "NM_004304.5",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "2p23.2-p23.1"
                  },
                  {
                    "name": "location_sortable",
                    "value": "02p23.2-p23.1"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Wild type"
              },
              {
                "name": "present",
                "value": true
              }
            ]
          },
          {
            "id": 35,
            "name": "Wild type EGFR",
            "genes": [
              {
                "id": 17,
                "name": "EGFR",
                "primaryCoding": {
                  "id": "hgnc:3236",
                  "code": "HGNC:3236",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"
                  ]
                },
                "mappings": [
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_005228.5",
                      "code": "NM_005228.5",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000146648",
                      "code": "ENSG00000146648",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000146648"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:1956",
                      "code": "1956",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/1956"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "7p11.2"
                  },
                  {
                    "name": "location_sortable",
                    "value": "07p11.2"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Wild type"
              },
              {
                "name": "present",
                "value": true
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 47,
          "conceptType": "Disease",
          "name": "Non-Small Cell Lung Cancer",
          "primaryCoding": {
            "id": "oncotree:NSCLC",
            "code": "NSCLC",
            "name": "Non-Small Cell Lung Cancer",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 22,
          "membership_operator": "AND",
          "therapies": [
            {
              "id": 45,
              "conceptType": "Drug",
              "name": "Tremelimumab",
              "primaryCoding": {
                "id": "ncit:C49085",
                "code": "C49085",
                "name": "Tremelimumab",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:2619313",
                    "code": "2619313",
                    "name": "tremelimumab",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2619313"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:741851",
                    "code": "741851",
                    "name": "tremelimumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/741851"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:2054101000122107",
                    "code": "2054101000122107",
                    "name": "Tremelimumab",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=2054101000122107&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1450218",
                    "code": "1450218",
                    "name": "Tremelimumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1450218"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "CTLA-4 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Immunotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 50,
              "conceptType": "Drug",
              "name": "Gemcitabine",
              "primaryCoding": {
                "id": "ncit:C66876",
                "code": "C66876",
                "name": "Gemcitabine",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:12574",
                    "code": "12574",
                    "name": "gemcitabine",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=12574"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1314924",
                    "code": "1314924",
                    "name": "gemcitabine",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1314924"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:386920008",
                    "code": "386920008",
                    "name": "Gemcitabine",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=386920008&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4305105",
                    "code": "4305105",
                    "name": "Gemcitabine",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4305105"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Antimetabolite"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 37,
              "conceptType": "Drug",
              "name": "Carboplatin",
              "primaryCoding": {
                "id": "ncit:C1282",
                "code": "C1282",
                "name": "Carboplatin",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:40048",
                    "code": "40048",
                    "name": "carboplatin",
                    "system": "RxNorm",
                    "systemVersion": "20250602",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=40048"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4299846",
                    "code": "4299846",
                    "name": "Carboplatin",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4299846"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:386905002",
                    "code": "386905002",
                    "name": "Carboplatin",
                    "system": "SNOMED",
                    "systemVersion": "2026-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=386905002&edition=MAIN/2026-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1344905",
                    "code": "1344905",
                    "name": "carboplatin",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1344905"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Platinum-based chemotherapy"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 44,
              "conceptType": "Drug",
              "name": "Durvalumab",
              "primaryCoding": {
                "id": "ncit:C103194",
                "code": "C103194",
                "name": "Durvalumab",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:1919503",
                    "code": "1919503",
                    "name": "durvalumab",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1919503"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1594034",
                    "code": "1594034",
                    "name": "durvalumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1594034"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:735230005",
                    "code": "735230005",
                    "name": "Durvalumab",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=735230005&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:42536415",
                    "code": "42536415",
                    "name": "Durvalumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/42536415"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "PD-1/PD-L1 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Immunotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            }
          ]
        }
      }
    }
  ]
}